You are here: Industry Insights > Market News > Sanofi to invest in Canadian vaccine facility

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Avatrombopag Maleate

BioHub® Magnetic Separator

Avatrombopag

Ursodeoxycholic acid

Troxerutin

CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

Sanofi to invest in Canadian vaccine facility

biospectrumasiaApril 16, 2018

Tag: Sanofi , Vaccine

Favorites

Sanofi is investing €350M (CAD $500M) to construct a new state-of-art vaccine manufacturing facility at the Sanofi Pasteur Canadian headquarters in Toronto, Ontario. The investment bolsters the company's Canadian operations and its commitment to advancing public health around the world.

The new facility will allow Sanofi Pasteur, the vaccines global business unit of Sanofi, to meet the growing demand of five-component acellular pertussis (5-acP) antigen. Upon completion in 2021, the new building will also be equipped to produce the antigens used in the diphtheria and tetanus vaccines.

Register as Visitor to CPhI China 2018!

Previous:Capital raise for Vermillion

Next:Australian researchers invent tiny fibre optic probe

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Sanofi to invest in Canadian vaccine facility | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Group A and C Meningococcal+Haemophilus Type B Conjugate Vaccine

Enterovirus Type 71 Vaccine, Inactivated (Human Diploid Cell)

Hualan Biological Recombinant Hepatitis B Vaccine (Hansenula polymorpha)

2024-2025 quadrivalent/trivalent flu vaccine

2024-2025 quadrivalent flu vaccine

H7N9 Inactivated Influenza Vaccine-HUALAN

Recombinant Hepatitis B Vaccine(Saccharomyces Cerevisiae)

Recommended flu vaccine 2023-2024 by WHO

IPV(Inactivated Poliovirus Vaccine)

Meningococcal Group A&C Polysaccharide Conjugate Vaccine

Sanofi to invest in Canadian vaccine facility

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may likeMore>>

You may like
More>>